Risk of Symptomatic Infection During a Second Coronavirus Disease 2019 Wave in Severe Acute Respiratory Syndrome Coronavirus 2-Seropositive Individuals

Clin Infect Dis. 2022 Mar 9;74(5):893-896. doi: 10.1093/cid/ciab556.

Abstract

We analyzed 221 coronavirus disease 2019 cases identified between June 2020 and January 2021 in 6074 individuals screened for immunoglobulin G antibodies in May 2020, representing 77% of residents of 5 Italian municipalities. The relative risk of developing symptomatic infection in seropositive participants was 0.055 (95% confidence interval, .014-.220).

Keywords: COVID-19; SARS-CoV-2; natural immunity; reinfection risk; serological screening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19*
  • Humans
  • Immunoglobulin G
  • Reinfection
  • SARS-CoV-2*

Substances

  • Antibodies, Viral
  • Immunoglobulin G